Clinical Trial: An Open Label, Single Dose Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure: a Phase I Clinical Trial

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT04846816) titled 'An Open Label, Single Dose Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure: a Phase I Clinical Trial' on April 12.

Brief Summary: This is a single-centre, prospective, open-label, non-comparative clinical trial assessing the on-body performance of an investigational drug delivery device (SQIN-Infusor) in patients hospitalised due to HF.

Study Type: Interventional

Condition: Heart Failure

Intervention: Combination Product: SQIN-01

The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor ...